Adverse effects: Extrapyramidal symptoms (Simpson‐Angus) · patients with sexual dysfunction due to antipsychotic drug therapy
1 finding from 1 review
Life skills: No important change kitchen skills Royal Edinburgh Occupational Therapy Assessment Form · patients with chronic mental illnesses
1 finding from 1 review
Clinically significant response on global state · non response in schizophrenia
It is very uncertain whether increasing the antipsychotic dose changes global state: Clinically relevant response – as defined by trial… compared with switching the antipsychotic drug (very low certainty).
1 finding from 1 review
Leaving the study early ‐ due to adverse effects (short term) · non response in schizophrenia
1 finding from 1 review
Acceptability of treatment ‐ leaving the study early · non response in schizophrenia
1 finding from 1 review
Mental state: psychopathology Total endpoint data, BPRS (higher score = worse, scale from: 0‐126) · non response in schizophrenia
1 finding from 1 review
Risk for at least one adverse event per patient · non response in schizophrenia
1 finding from 1 review
Service use: 1. Average number of days in hospital per month ‐ by about 24 months · non response in schizophrenia
1 finding from 1 review
Average change in quality of life/satisfaction · non response in schizophrenia
1 finding from 1 review
Intervention not reported
Weight: Gain‐more than or equal to 7% from baseline · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems
The intervention showed no clear difference in weight: Gain‐more than or equal to 7% from baseline (moderate certainty).
1 finding from 1 review
Intervention not reported
Weight: BMI not improved · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems
1 finding from 1 review
Intervention not reported
Physiological measure: Metabolic syndrome · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems
1 finding from 1 review
Intervention not reported
Global state: Average change (CGI‐I, high=good) · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems
1 finding from 1 review
Intervention not reported
Mental state: Average change (PANSS, high decline=good) · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems
1 finding from 1 review
Intervention not reported
Adverse events: Any event · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems
The intervention showed no clear difference in adverse events: Any event (moderate certainty).
1 finding from 1 review
Intervention not reported
Satisfaction with care: Loss to · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems
It is very uncertain whether the intervention changes satisfaction with care: Loss to (very low certainty).
1 finding from 1 review